Novartis AG and Molecular Partners AG will halt recruitment of hospitalized COVID-19 patients in the ensovibep arm of the Phase III ACTIV-3 study after it failed a futility analysis. Their attentions now turn to the candidate’s potential in a non-hospitalized setting in another Phase II/III study, EMPATHY.
Molecular’s lead infectious disease candidate, ensovibep, did not meet the thresholds necessary to continue enrolment, the data and safety monitoring board said
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?